Clinical Data Management Articles & Analysis
8 news found
Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure. ...
What can clinical trial managers do to hone their skills and be prepared for future opportunities? ...
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has appointed Ms Cassandra Harrison to the position of Vice President (VP) Clinical Operations and Data Management. Ms Harrison joins Chimeric with more than 10 ...
"Up to 40% of patients who undergo radical prostatectomy, and up to 50% of patients who undergo radiation therapy will develop local or distant recurrences within 10 years, and the ability to determine the extent and location of recurrent prostate cancer to inform appropriate clinical management for these men is key for physicians and their patients," said David ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced results of a secondary, post-hoc analysis of data from the prospective LOCATE and FALCON clinical trials that evaluated the impact of Axumin® (fluciclovine F 18) PET/CT imaging on ...
“Adoption of DCT technologies that are capable of not only performing individually as best-in-class solutions but are also designed and engineered to be at optimal performance in an integrated clinical data mesh are the key to meeting demands and leading in the rapidly changing landscape of clinical trials,” says Brad Cottreau, Vice ...
From this day forward, we will be sharing interesting (in our opinion) stories from the field of clinical biostatistics, data management in clinical trials and reporting news from a pioneering journey we started a few years ago, which is about bringing the R statistical package and other Open Source solutions to ...
The presence of high LCP was an independent predictor of patient-level non-culprit events and lesion-specific events. Data showed a 2.3-fold and 7.8-fold higher likelihood for patient-level and lesion-level risks, respectively. ...